tradingkey.logo

Atea Pharmaceuticals Inc <AVIR.OQ> expected to post a loss of 41 cents a share - Earnings Preview

ReutersMay 9, 2025 11:04 PM
  • Atea Pharmaceuticals Inc AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Atea Pharmaceuticals Inc is for a loss of 41 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Atea Pharmaceuticals Inc is $6.00​, above​ its last closing price of $2.72. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.38

-0.37

-0.40

Missed

-8.1

Sep. 30 2024

-0.46

-0.49

-0.37

Beat

25.3

Jun. 30 2024

-0.76

-0.76

-0.48

Beat

37.3​

Mar. 31 2024

-0.63

-0.61

-0.75

Missed

-23.6

​​Dec. 31 2023

-0.49

-0.50

-0.47

Beat

5.4

Sep. 30 2023

-0.45

-0.48

-0.40

Beat

16.1​

Jun. 30 2023

-0.45

-0.47

-0.34

Beat

27.7

Mar. 31 2023

-0.47

-0.48

-0.43

Beat

9.9

This summary was machine generated May 9 at 23:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI